ACRV
Companies
NASDAQ
Acrivon Therapeutics Inc.
Health Care
$1.25
-$4.77 (-79.24%)
Price Chart
Overview
About ACRV
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Market Cap
$223.9M
Volume
583.0K
Avg. Volume
215.8K
P/E Ratio
-0.5148148
Dividend Yield
122.38%
Employees
51.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.50
Low Correlation
Volatility
High (0.91)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ACRV shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025